Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.72 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.72 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.72 |
| ▸ | FYN | P06241 | 1/20 | 0.70 |
| ▸ | SRC | P12931 | 1/20 | 0.70 |
| ▸ | BLK | P51451 | 1/20 | 0.70 |
| ▸ | BMX | P51813 | 1/20 | 0.70 |
| ▸ | JAK3 | P52333 | 1/20 | 0.70 |
| ▸ | BTK | Q06187 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29918398 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4ABCG2FYN | |
| SCHEMBL8781957 | 0.94 | EGFR (0.88) | EGFRERBB2ERBB4ABCG2 | |
| SCHEMBL28762044 | 0.93 | EGFR (0.88) | EGFRERBB2ERBB4ABCG2FYN | |
| SCHEMBL2986436 | 0.91 | EGFR (0.84) | EGFRERBB2 | |
| SCHEMBL15782168 | 0.90 | EGFR (0.82) | EGFRERBB2ERBB4ABCG2FYN | |
| SCHEMBL28006366 | 0.90 | EGFR (0.82) | EGFRERBB2ERBB4ABCG2FYN | |
| SCHEMBL4585935 | 0.89 | EGFR (1.00) | EGFRERBB2ERBB4FYNSRC | |
| SCHEMBL4586021 | 0.89 | EGFR (1.00) | EGFRERBB2ERBB4ABCG2 | |
| SCHEMBL12012727 | 0.88 | EGFR (1.00) | EGFRERBB2ERBB4ABCG2FYN | |
| SCHEMBL15782176 | 0.88 | EGFR (0.78) | EGFRERBB2ERBB4ABCG2FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| CN-118141921-A | Use of CAMK2 inhibitors for the preparation of a medicament for reducing resistance to EGFR-driven cancers | 四川大学 | 2024-06-07 | — | — | CN | disclosed |
| EP-3039122-B1 | GENERATION OF ENDOCRINE PROGENITOR CELLS FROM HUMAN PLURIPOTENT STEM CELLS USING SMALL MOLECULES | NOVO NORDISK AS (DK) | 2019-07-17 | — | — | EP | disclosed |
| US-10034931-B2 | Use of EGFR pathway inhibitors to increase immune responses to antigens | EMORY UNIVERSITY (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160228533-A1 | Use of EGFR Pathway Inhibitors to Increase Immune Responses to Antigens | EMORY UNIVERSITY (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160208215-A1 | Generation of Endocrine Progenitor Cells from Human Pluripotent Stem Cells Using Small Molecules | TAKARA BIO EUROPE AB (SE) | 2016-07-21 | — | — | US | disclosed |
| WO-2015042567-A1 | USE OF EGFR PATHWAY INHIBITORS TO INCREASE IMMUNE RESPONSES TO ANTIGENS | EMORY UNIVERSITY (US) | 2015-03-26 | — | — | WO | disclosed |
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| CN-1923818-A | Irreversible inhibitors of tyrosine kinases | WARNER LAMBERT CO (US) | 2007-03-07 | — | — | CN | disclosed |
| US-20060167026-A1 | Antipsychotic molecular-targeting epithelial growth factor receptor | HIROYUKI NAWA (JP) | 2006-07-27 | — | — | US | disclosed |
| CN-1495172-A | Irreversible inhibitors of tyrosine kinases | ��ʲ | 2004-05-12 | — | — | CN | disclosed |
| CN-1145614-C | Irreversible inhibitors of tyrosine kinases, their pharmaceutical use and pharmaceutical compositions | ��ʲ | 2004-04-14 | — | — | CN | disclosed |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-12-11 | — | — | US | disclosed |
| US-6602863-B1 | Irreversible inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY | 2003-08-05 | — | — | US | disclosed |
| EP-0892789-B1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2002-02-27 | — | — | EP | disclosed |
| US-6344459-B1 | TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS, ENDOMETRIOSIS, AND PSORIASIS | WARNER-LAMBERT COMPANY | 2002-02-05 | — | — | US | disclosed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885ERBB2 1/4885ERBB4 13/4885 |
| US-20060167026-A1 | Antipsychotic molecular-targeting epithelial growth factor receptor | EGFR, BDNF, NTRK2 | EGFR 1/4885ERBB2 7/4885ERBB4 9/4885 |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | EGFR 1445/4885ERBB2 1351/4885ERBB4 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.